Dr. Meijia Yang, Chief Scientific Officer

• Ph.D., Biochemistry, University of Basel, Switzerland

• Postdoctoral Fellow, State University of New York at Stony Brook, USA

• Over 30 years of leadership experience in MNC drug R&D organizations

• Founded Boston 3T Biotechnologies, the predecessor of ELT Boston Research Center, in 2013 to focus on global innovative cell and protein drug research and development

• Innovated CAR-T cell therapies and long-acting protein technologies

• Leading international experience and capabilities in new biological entity discovery